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Literature Review & Rationale 
In the United States alone, approximately 1 in 8 women will develop invasive breast 
cancer in her lifetime making breast cancer the second most common and second most lethal 
cancer amongst women.  According to American Cancer Society, 246,660 new cases of breast 
cancer will be diagnosed this year in 2016
1
.   Not only is a breast cancer patient affected
physically, but they will also be affected emotionally and psychologically.   The effects are 




There are many risk factors which can increase a woman’s likelihood of developing 
breast cancer.  Unfortunately, many of these factors are uncontrollable such as: being female, 
increased age, genetic factors, and family history.  However, there are many factors that are 
controllable such as: exercise, weight, various environmental factors, and diet
1
.
The metastases of breast cancer are among one of the highest rates compared to other 
cancers and leads to a higher rate of mortality
3
. Metastasis is the development of secondary
malignant growth that in sites distal from the primary tumor.  It has been estimated that about 20-
30% of breast cancer cases lead to metastasis
4
 and an estimated 40,450 women will die from
breast cancer in 2016
1
. There are many different sites in the body where it can metastasize; each
different site will have different behaviors and severity
3
.  The most common sites of breast
cancer metastasis is lungs, brain, liver, and bone. The variations in behavior and severity of 
metastasis support the seed and soil hypothesis. The seed and soil hypothesis explains that a 
primary tumor may metastasize (the seed) and begin growing at a distal site (the soil). These 
distant sites display differential characteristics in gene expression, growth factors, and receptors
3
.
Over the years, evidence has emerged suggesting vitamin D may reduce the risk of breast 
cancer although the relationship is not fully understood. Evidence shows that lower vitamin D is 
associated with an increased risk of metastasis, but the mechanistic basis for this is not well 
known. Studies have additionally identified an inverse association between serum 25  
hydroxyvitamin D (25(OH)D) levels, a marker for vitamin D status, and the risk of breast 
cancer
9
. The active form of vitamin D, 1,25dihydroxyvitamin D (1,25 (OH)2D) has been shown
to regulate a variety of components of cancer progression, including inhibiting cell proliferation 




 There are two primary forms of vitamin D obtainable from the environment. 
Cholecalciferol, or vitamin D3, is produced from cholesterol in the skin when exposed to sunlight 
or ultraviolet light. Ergocalciferol, or vitamin D2, is obtained from the diet. Vitamin D3 is 
hydroxylated in the liver to form its dominant circulating, inactive form, 25(OH)D
6
. This
inactive form 25(OH)D is converted to its active form1,25(OH)2D by the enzyme 25-
hydroxyvitamin D1α-hydroxylase.  This process occurs in the proximal tubules of the kidney as 
well as in many other tissues including: immune system, skin, adrenal medulla, pancreatic islet 
cells, colon, and breast
7
.  The active form, 1,25(OH)2D, is a secosteroid that is known for its role
in regulating calcium and phosphate homeostasis in part through parathyroid hormone secretion 
via stimulating absorption from the gut, increasing calcium absorption and renal reabsorption 
6
.
There are a range of other cellular functions associated with 1,25(OH)2D including: 
antiproliferation, immunomodulatory properties, disease prevention
5
, differentiation, and many
others
6
. The nuclear vitamin D receptor (VDR) binds to 1,25(OH)2D functioning as a
transcription factor in both normal and neoplastic cells
5
. VDR binds to one of the retinoid X
receptors, forming a dimer that interacts with coactivators assisting in recruiting the RNA 
polymerase II complex. These coactivators are responsible for activating various gene 
expression
8
. Figure 1 represents the metabolism of vitamin D.
In breast cancer cells, regulation of the cell cycle is transformed
12
.  Previous findings
from our lab have shown an association between 1,25(OH)2D treatment with decreased viable 
cell number, induction of cell apoptosis, and cell cycle regulation by inducing G1/G0 cell cycle 
arrest. These results were modeled using MFC10A cells transfected with the Harvey ras 
oncogene (MCF10A-ras). This inhibition of cell cycle proliferation could contribute to the 
decrease in viable cell number via 1,25(OH)2D and therefore preventing breast cancer 
progression and cell cycle regulation. 
The cell cycle is composed of a series of events that control the replication of the genetic 
material and division of the cell
13
.  The process is tightly controlled and divided into phases
12
. G0
Figure 1. Vitamin D Metabolism. 
The metabolism of vitamin D3 into 
its active form, 
1,25dihydroxyvitamin D3 
(1,25(OH)2D3) requires several steps. 
The active form functions as a 
hormone and transcription factor to 
its receptor vitamin D receptor 
(VDR). VDR forms a dimer with 
retinoid X receptor (RXR) and 
functions to recruit the RNA 
polymerase II transcription complex
8
.
is a separate state in which cells are in a quiescent state. During proliferation the cell transitions 
through G1, a gap phase in which the cell increases in size as it grows and synthesizes mRNA 
and proteins. The cell then moves  into the S phase, in which precise DNA replication occurs in 
the nucleus. Next, the cell enters another gap phase, G2, as the cell continues to grow. Finally, 
the cell will enter M phase, where mitosis occurs and the cell divides via cytokinesis
13
. Figure 1
shows a summary of the steps of the cell cycle. 
Throughout the cell cycle, there are various cell cycle check points that function to ensure 
accurate propagation. There are numerous molecules and proteins that are utilized as regulators 
of the cell cycle to ensure proper transition
12
. Control of the G2/M transition has been found to be
associated with cancer because it may result in chromosomal aberrations. The G1/S transition 
may be altered in breast cancer cells, where oncogenes may disrupt the normal function of genes 
and tumor suppressors. The arrest of cells in the G1/S phase prevents them from proliferating 
and further growth which is considered an essential component of cancer cells. During cancer 
development, several cell cycle regulator molecules have been found to be overexpressed, 
leading to loss of normal growth regulation and increased proliferation
 12
. The active form of
vitamin D has been known to play a role in cell cycle arrest in breast cancer cells
10, 11
. It has been






Figure 1. The phases of the cell cycle. The 
cell cycle progress from G1 gap phase (growth 
and protein synthesis) to S phase (synthesis) to 
G2 gap phase (growth) and finally through M 
phase (mitosis via cytokinesis). 
10 
G1/G0 cell cycle arrest and promote apoptosis
14
. One type of cell cycle regulator, cyclin-
dependent kinase inhibitors (CDI’s) negatively modulate the progression of the cell cycle. One 
CDI in particular, p27
Kip1
, interacts with CDK2 and CDK4 by inhibiting cell cycle progression at
the G1 phase when grown with 1,25(OH)2D
15
. Studies have shown that the addition of
1,25(OH)2D to neoplastic cells is associated with an increase in p27
Kip1
, suggesting that this
protein may be a principle mediator in 1,25(OH)2D G1 cell cycle arrest
15
.
Another possible mechanism of dysregulation in cancer that affects cell cycle may be 
signal transduction pathways. One of these pathways includes the MAP kinase which is a part of 
signaling cascade pathway that regulates gene transcription
16
 important in cell cycle regulation
Recent studies have shown that Src, a non-receptor tyrosine kinase, becomes more 
phosphorylated with the addition of 1,25(OH)2D, inhibiting its kinase activity. This results in 
downstream MAPK (ERK-1 and ERK-2 MAP kinases) to be repressed
16
, suggesting that
1,25(OH)2D may also regulate cell cycle through the Src/MAP kinase signaling pathway. 
Previous findings from our lab have shown an association between 1,25(OH)2D treatment 
with decreased viable cell number, induction of cell apoptosis, and cell cycle regulation by 
inducing G1/G0 cell cycle arrest. These results were modeled using MFC10A cells transfected 
with the Harvey ras oncogene (MCF10A-ras). This inhibition of cell cycle proliferation could 
contribute to the decrease in viable cell number via 1,25(OH)2D and therefore preventing breast 
cancer progression. The purpose of this study is to investigate the role of 1,25(OH)2D in cell 
cycle regulation and G1/G0 arrest in additional human breast epithelial cells in progression to 
cancer. Therefore, it is hypothesized that the addition of 1,25(OH)2D to the four cell lines used 
will induce G1/G0 cell cycle arrest by increasing the proportion of cells found in G1/G0 phase. 
To study cancer progression and prevention, it is important to use appropriate models. 
The most commonly used and appropriate model for studying breast cancer progression are the 
MCF10A series (MCF10A, MCF10A-Ras, MCF10A-ErbB2, and MCF10CA1). MCF10A cells 
were derived from benign breast tissue that spontaneously immortalized and are proposedly the 
most common cell line used to model breast cells
17
. These cells have proliferative properties, but
do not express the estrogen receptor. They contain a deletion in the locus that contains genes 
important for regulation of senescence and overexpression of the Myc gene. However, the 
MCF10A cells express a basal-like phenotype, yet express some features resembling 
mesenchymal cancer cells.  This cell line led to the establishment of a series of cell lines 
including more aggressive breast cancer lines
17
. The MCF10A-Ras cell line serves as a model for
the Harvey-Ras (Ha-Ras) proto-oncogenic effector utilized for growth-dependent induction of 
several growth factors and cytokines
18
. Ha-Ras induced tumors contain activated mitogen-
activated protein kinase (MAPK) signaling cascades. Ras activation is also involved in 
overexpression of ErbB2 in breast tumors.  Mutations in Ras are rare in breast cancers, but Ras is 




The MCF10A-ErbB2 cell line contains a transformed ErbB2 gene. ErbB2 is an 
oncoprotein in the family of epidermal growth factor receptors (EFG) of receptor tyrosine 
kinases
20
. However, ErbB2 does not directly bind growth factors because it does not contain a
ligand binding domain. Instead, it forms a heterodimer with other EFG receptors that are bound 
to ligands. This interaction leads to increased ligand binding and increased kinase-mediated 
activation of downstream signaling pathways. Overexpression and amplification of ErbB2 is 
found in cancers
20
, including about 1 in 4 cases of invasive breast cancer
21
. The overexpression
of ErbB2 has also been shown to initiate breast cancer invasion and metastasis, leading to poor 
patient survival.  The MCF10CA1a cell line is a metastatic line derived from the MCF10A-Ras 
cells
22
.  These cells are oncogenic, fully malignant, and are histologically undifferentiated,
morphologically variable, and anchorage-independent
23
.  The MCF10CA1a cell line serves as a
valuable model for analyzing the oncogenic potential of genes of interest
22 
There is evidence that a higher vitamin D status is associated with a decreased risk of 
metastasis, but the mechanistic basis for this is still under investigation. In numerous studies, 
1,25(OH)2D has been shown to inhibit cell differentiation, apoptosis promotion, cell 
proliferation, and cell cycle arrest in breast cancer cells. Cell proliferation is normally controlled 
by the cell cycle, which is composed of a series of events that control the replication of the 
genetic material and division of the cell. The cell cycle process is tightly controlled and divided 
into phases. In breast cancer cells, normal regulation of the cell cycle is typically altered in order 
to promote increased cell proliferation. Therefore, the regulation of the cell cycle is considered to 
be a potential target for cancer therapy. Previous research in our lab demonstrated that MCF10A-
ras cells treated with 1,25(OH)2D induced G1 cell cycle arrest. These results led to the interest in 
further investigating the effects of 1,25(OH)2D in human breast epithelial cells during cancer 
progression. 
Purpose 
The purpose of this study is to investigate the role of 1,25(OH)2D in cell cycle regulation and 
G1/G0 arrest in human breast epithelial cells in progression to cancer. 
Study Design & Methods 
Cell Lines 
The cell lines used for experiments were MCF10A, MCF10A-ras, MCF10A-ErbB2, and 
MCF10CA1a. MCF10A cells are benign human breast epithelial cells
17
. MCF10A-Ras are
Harvey-Ras oncogene transfected MCF10A cells
18
. MCF10A-ErbB2 are ErbB2/HER2/Neu
oncogene transfected MCF10A cells
20





Cells were grown and maintained in culture Dulbecco’s Modified Eagle Medium/F12 
(DMEM/F12) (1:1) nutrient mix containing 5% horse serum, 1% penicillin/streptomycin (Life 
Technologies, Gibco-BRL, Rockville, MD). For MCF10A, MCF10A-ErbB2, and MC10A-Ras: 
10mg/L insulin, 20ug/L epidermal growth factor, 50mg/L hydrocortisone (Sigma-Aldrich, St. 
Louis, MO), and 50ug/L cholera toxin (Calbiochem, Darmstadt, Germany) were supplemented to 
the media. Cells were plated at 300,000 cells per 60mm culture dish and allowed to attach 
overnight. Then 10nM 1,25(OH)2D (Biomol, Plymouth Meeting, PA) treatment was delivered to 
cells in 100% ethanol at a final ethanol concentration of <1% for 72 hours.  Media supplemented 
with 1,25(OH)2D was replaced every 24 hours during the treatment period. Plates were kept in a 
humidified environment at 37
 
C. 
Cell Cycle Measurement 
Flow cytometry was used for cell cycle measurements. From each sample, 1x10
6
 cells
 were harvested using phosphate buffered saline in a single cell suspension. Cells were fixed with 
ice cold ethanol then pretreated with 0.2 mg/mL Rnase A, and stained with 10 ug/mL propidium 
iodide (Sigma-Aldrich, St. Louis, MO). Cell cycle quantifications were achieved using flow 
cytometry analysis with a Beckman Coulter FC500 flow cytometer equipped with a 488 nm 
laser. The results were analyzed with FloJo (Tree Star, Inc., Ashland, OR).  Results were 
expressed as percentage of total cells arrested in each phase in the cell cycle. 
Figure 2. Cytomics FC 500 Flow Cytometer. Cells were stained with propidium iodide (PI) 
which binds to double stranded DNA by intercalating between base pairs. The flow cytometer 
emits a laser light that passes through one cell at a time. A detection apparatus absorbs the 
refracted light at FL3 (670LP, red). The fluorescence intensity is proportional to the DNA 




Results were compared using the Student’s t-test including the means +/- SD. P-values < 
0.05 are considered significant. 
Results 
Impact of 1,25(OH)2D on cell cycle regulation in MCF10A, MFC10A-Ras, MCF10A-ErbB2, and 
MCF10CA1a cels. 
In order to determine if 1,25(OH)2D regulates the cell cycle in breast epithelial cells, 
analysis of cell cycle phases was determined in MCF10A, MFC10A-Ras, MCF10A-ErbB2, and 
MCF10CA1a cells. In MCF10A cells, the addition of 1,25(OH)2D (10 nM) significantly 
increased the number of cells arrested in the G1/G0 phase (p=0.03).  Treatment with 1,25(OH)2D 
did not significantly change the number of cells in G2 relative to the vehicle (p=0.21). 
Figure 3. 1,25(OH)2D Regulation of MCF10A Cell Cycle. Cells were treated 


















































cycle analysis and quantification by flow cytometry. Bars with asterisks(*) 
indicate significance (p < 0.05) by Student’s t-test including the means +/- SD. 
In MCF10A-Ras cells, the addition of 1,25(OH)2D (10 nM) significantly increased the 
number of cells arrested in the G1/G0 phase (p=0.002). The number of cells in G2 significantly 
decreased relative to the vehicle with 1,25(OH)2D treatment (p=0.0006). 
Figure 4. 1,25(OH)2D Regulation of MCF10A-Ras Cell Cycle. Cells were 
treated with either vehicle or 10 nM 1,25(OH)2D for 72 hours, and harvested for 
cell cycle analysis and quantification by flow cytometry. Bars with asterisks(*) 



















































In MCF10A-ErbB2 cells, the addition of  1,25(OH)2D (10 nM) significantly increased the 
number of cells arrested in the G1/G0 phase (p=0.01). With 1,25(OH)2D treatment, the number 
of cells in G2 did not show a significant change relative to the vehicle (p=0.83). 
Figure 5. 1,25(OH)2D Regulation of MCF10A-ErbB2 Cell Cycle. Cells were 
treated with either vehicle or 10nM 1,25(OH)2D for 72 hours, and harvested for 
cell cycle analysis and quantification by flow cytometry. Bars with asterisks(*) 



















































In MCF10CA1a cells, the addition of 1,25(OH)2D (10 nM) significantly increased the 
number of cells arrested in the G1/G0 phase (p=0.00005). The number of cells in G2 did not 
significantly change relative to the vehicle with 1,25(OH)2D treatement (p=0.23). 
Figure 6. 1,25(OH)2D Regulation of MCF10CA1a Cell Cycle. Cells were 
treated with either vehicle or 10nM 1,25(OH)2D for 72 hours, and harvested for 
cell cycle analysis and quantification by flow cytometry. Bars with asterisks(*) 
indicate significance (p < 0.05) by Student’s t-test including the means +/- SD. 
Discussion 
There is evidence that higher vitamin D status is associated with a decreased risk of 
metastasis, but the mechanistic basis has not been determined. In numerous studies, 1,25(OH)2D 


















































apoptosis in breast cancer cells. Previous studies in our lab have shown that 1,25(OH)2D arrests 
cells in the cell cycle and induces apoptosis in MCF10A and MCF10A-Ras cell lines. In the 
current study, it is demonstrated that 1,25(OH)2D regulates the cell cycle by increasing the 
percentage of cells arrested in the G1/G0 phase of the cell cycle. All four cell lines modeled for 
breast cancer progression showed significant increases when treated for 72 hours: MCF10A 
(P=0.03), MCF10A-ras (P=0.002), MCF10A-ErbB2 (P=0.01), and MCF10CA1a (P= 0.00005). 
The results from this study are consistent with previous results from our lab using 
MCF10A and MCF10A-Ras cells in which 1,25(OH)2D arrested cells in the G1/G0 phase of the 
cell cycle. This study re-analyzed the MCF10A and MCF10A-Ras cells as well as two other cell 
lines, MCF10A-ErbB2 and MCF10CA1a and the increased number of cells arrest in the G1/G0 
phase further supports the hypothesis and previous findings. 
There have been several possible mechanisms proposed to demonstrate the role of 
vitamin D on the regulation of the cell cycle. Studies have shown that 1,25(OH)2D plays a role in 
the expression of specific cell cycle regulators such as cyclin-dependent kinase inhibitors 





progression at the G1 phase through the  interactions with CDK2 and CDK4
15
. Another proposed
mechanism of 1,25(OH)2D regulation is via signal transduction pathways such as Src and the 
MAP kinase cascade which regulate gene transcription . An upstream regulator of MAP kinase, 
Src, may be inhibited by phosphorylation due to the addition of 1,25(OH)2D, resulting in 
downstream repression of MAPK
16
. There is evidence that 1,25(OH)2D regulates various
pathways in gene transcription and cell cycle regulation that may lead to the arrest in G1/G0 
phase and therefore reduction in cell proliferation and apoptosis. 
 These results indicate that 1,25(OH)2D is associated with regulating the cell cycle, 
although the exact mechanism is still under consideration. Inhibition of the cell cycle may 
explain the mechanism of vitamin D to inhibit breast cancer progression.  Vitamin D may be an 
essential molecule for inhibiting cell growth and proliferation which may contribute to its role in 
breast cancer progression.  
 Understandings on the mechanisms by which vitamin D inhibits breast cancer 
development and metastasis is important in order to design clinical trials to test the effect in 
humans.  Thus, the information from this study will potentially contribute to developing 
recommendations for vitamin D intake that will prevent breast cancer development and 
metastasis.   
 
Conclusion 
 In MCF10A, MCF10A-Ras, MFC10A-ErbB2, and MCF10CA1a breast epithelial cell 
lines, 1,25(OH)2D treatment for 72 hours increased the percent of cells arrested in G1/G0 phase 
of the cell cycle. This indicates that these cells may be inhibited from progressing through the 
cell cycle due to arrest in the G1/G0 phase. Therefore, inhibition of the cell cycle may explain 
the effect of vitamin D to inhibit breast cancer progression. These results support the evidence 
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